poisar

Stocks · News reference

Boston Scientific Sees Q3 Adj EPS $0.80-$0.82 vs $0.83 Est; Sees Sales $5.217B-$5.318B vs $5.358B Est

BenzingaJul 29, 2026, 10:34 AMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Jul 29, 2026, 10:34 AM
Checked
Jul 29, 2026, 10:33 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncAug 26, 2026, 11:57 AMResearchandmarkets.Com

    Atrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic

    The global atrial fibrillation treatment devices market is expected to grow at a 13.1% CAGR from $9.6 billion in 2026 to $29 billion by 2035, driven by aging populations, rising AF prevalence affecting 50-60 million people worldwide, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Pulsed field ablation is forecast to generate over 60% of market revenue by 2035, while North America will retain approximately 50% of global market share. Asia-Pacific is expected to register the fastest regional growth.

    Read original at globenewswire-inc